Effect of Probiotics and M esalazine in the treatment of inflammatory bowel disease
ZHANG Hong-wei1 ZENG Jing-ke2
1.Department of Internal Medicine,the Third Hospital Affiliated to Gannan School of Medicine,Jiangxi Province,Ganzhou 341000;
2.Department of Digestive and Liver Disease,the Fifth People′s Hospital in Ganzhou City,Jiangxi Province,Ganzhou 341007
Abstract：ObjectiveTo explore the efficacy and safety of Probiotics and Mesalazine in the treatment of inflammatory bowel disease.MethodsA total of 86 cases of inflammatory bowel disease patients treated in our hospital from August 2015 to December 2017 were selected as subjects.The patientswere divided into two groups according to the admission order,and each group was 43 cases.The patients in control group were given Mesalazine,the patients in the observation group were treated with Methalazine and Probiotics.The total effective rate,the incidence of adverse reaction,severity of of adverse reactions,the levels of inflammatory factors(Tumor necrosis factor-α [TNF-α],interleukin-6[IL-6]and interferon-γ [IFN-γ])and intestinal barrier function index(urine lactulose/mannitolrate[L/M])were compared between the two groups.ResultsAfter 8 weeks of treatment,the total effective rate of treatment in the observation group was higher than that of the control group,and the difference was statistically significant(P＜0.05).There was no significant difference in the incidence of adverse drug reactions between the two groups during the treatment(P＞0.05).There was no significant difference in the severity of adverse reactions between the two groups(P＞0.05).After 8 weeks of treatment,the levels of TNF-α,IL-6 and IFN-γ in the observation group were lower than those of the control group,the differenceswere statistically significant(P＜0.05).The level of L/M in the observation group was lower than that of the control group,and the difference was statistically significant(P＜0.05).ConclusionProbiotics combined with Mesalazine is effective in treating inflammatory bowel disease,which can improve intestinal barrier function,relieve inflammatory reaction,shorten treatment course,and with high safety.It isworth promoting.
章宏伟;曾敬科. 益生菌和美沙拉嗪治疗炎症性肠病的效果[J]. 中国当代医药, 2018, 25(16): 174-176转186.
ZHANG Hong-wei;ZENG Jing-ke. Effect of Probiotics and M esalazine in the treatment of inflammatory bowel disease. 中国当代医药, 2018, 25(16): 174-176转186.
Merkley SA，Beaulieu DB，Horst S，et al.Use of intravenous immunoglobulin for patients with inflammatory bowel disease with contraindications or who are unresponsive to conventional treatments[J].Gastroenterology，2014，146（5）：240.
[2]
Ashton，JJ，Coelho T，EnnisS，etal.Presentingphenotypeofpaediatric inflammatory bowel disease inWessex，Southern England 2010～2013[J].Actapaediatrica，2015，104（8）：831-837.
[3]
Kvasnovsky CL，Aujla U，Bjarnason I.Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease[J].Scand JGastroenterol，2015，50（3）：255-263.
京公网安备 11010502046607号